Dr Reddy’s sells of two migraine treatments to Upsher-Smith Laboratories in deal worth $110 million

pharmafile | June 17, 2019 | News story | Sales and Marketing  

Indian firm Dr Reddy’s has agreed to sell two migraine treatments to American firm Upsher-Smith Laboratories in a deal worth more than $110 million.

Dr Reddy’s will receive $70 million upfront and is eligible to receive an addition $40.5 million in milestone payments alongside quarterly royalties in return for Zembrace SymTouch (sumatriptan) and a nasal spray version of the drug Tosymra.

The FDA approved Zembrace SymTouch for adults with acute migraine episodes, with or without aura, who are inadequately managed with existing treatment regimens in 2016.

Tosymra was approved in for adults with acute migraine, with or without aura in Januyary of this year.

Dr Reddy’s chief executive GV Prasad said “this is a testament to our strong R&D capabilities, and delivering solutions to the unmet needs of patients.”

“In a short time, we created a well-recognised migraine specialty business in the US and we look forward to our partnership with Upsher-Smith,” he added.

Louis Goss

Related Content

No items found

Latest content